Canaccord raised the firm’s price target on OrthoPediatrics (KIDS) to $25 from $24 and keeps a Buy rating on the shares. The firm updated its model ahead of Q1 results. They continue to like the shares which is at the beginning of an NPL supercycle. The company executed on a beat in the Q4 while maintaining its conservative approach to guidance leaving out more variable elements which, if they improve, provide upside, while setting a baseline from which the company can profitably grow, evidenced by expectations for FCF breakeven in FY26.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KIDS:
- OrthoPediatrics Updates Disclosure on Direct Financial Obligation
- OrthoPediatrics Earnings Call Flags Profitable Turn
- Medicaid Policy Shifts Pose Significant Revenue and Margin Risks for OrthoPediatrics
- OrthoPediatrics price target raised to $20 from $19 at Truist
- Buy Rating Backed by Strong Q4 Execution, FCF Inflection, and Undemanding Valuation Upside